Experienced in WT1-Related Wilms Tumor Syndromes

Dr. Jonathan D. King

Oncology | Hematology Oncology | Hematology
Colorado West Healthcare System
2596 F Rd, 
Grand Junction, CO 
Experienced in WT1-Related Wilms Tumor Syndromes
Colorado West Healthcare System
2596 F Rd, 
Grand Junction, CO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jonathan King is an Oncologist and a Hematologist Oncology provider in Grand Junction, Colorado. Dr. King is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Metastatic Pleural Tumor, Familial Pancreatic Cancer, Lung Cancer, and Pleuropulmonary Blastoma.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Medical College Of Wisconsin
Specialties
Oncology
Hematology Oncology
Hematology
Licenses
Internal Medicine in CO
Hospital Affiliations
Intermountain Health St. Mary's Regional Hospital
Community Hospital
Montrose Regional Health
Moab Regional Hospital
Delta County Memorial Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Rocky Mountain Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Steward Health Care
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

COLORADO WEST HEALTHCARE SYSTEM
2596 F Rd, Grand Junction, CO 81505

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Enrollment Status: Active_not_recruiting
Publish Date: October 14, 2025
Intervention Type: Procedure, Drug
Study Drugs: Atezolizumab, Talazoparib
Study Phase: Phase 2
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 27, 2025
Intervention Type: Drug
Study Phase: Phase 3
Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial
Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
An Observational Study to Collect and Assess Tissue Samples From Subjects With One of Three Neoplastic Conditions (ANSWer)
An Observational Study to Collect and Assess Tissue Samples From Subjects With One of Three Neoplastic Conditions (ANSWer)
Enrollment Status: Completed
Publish Date: April 05, 2022
Intervention Type: Other
View 9 Less Clinical Trials

3 Total Publications

Response to Immunotherapy in Combination With Mitotane in Patients With Metastatic Adrenocortical Cancer.
Response to Immunotherapy in Combination With Mitotane in Patients With Metastatic Adrenocortical Cancer.
Journal: Journal of the Endocrine Society
Published: August 14, 2019
Similar Doctors
Experienced in WT1-Related Wilms Tumor Syndromes
Dr. Steven P. Emmons
Hematology Oncology | Hematology | Oncology
Experienced in WT1-Related Wilms Tumor Syndromes
Dr. Steven P. Emmons
Hematology Oncology | Hematology | Oncology

Montrose Memorial Hospital, Inc

2233 E Main St, 
Montrose, CO 
 (56.9 miles away)
Languages Spoken:
English
See accepted insurances

Steven Emmons is a Hematologist Oncology specialist and a Hematologist in Montrose, Colorado. Dr. Emmons is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Pleuropulmonary Blastoma, Familial Colorectal Cancer, Lung Cancer, and Small Cell Lung Cancer (SCLC).

Experienced in WT1-Related Wilms Tumor Syndromes
Dr. Joanne F. Virgilio
Hematology Oncology | Oncology | Hematology
Experienced in WT1-Related Wilms Tumor Syndromes
Dr. Joanne F. Virgilio
Hematology Oncology | Oncology | Hematology

Colorado West Healthcare System

2596 F Rd, 
Grand Junction, CO 
 (0.1 miles away)
970-254-3180
Languages Spoken:
English
See accepted insurances

Joanne Virgilio is a Hematologist Oncology specialist and an Oncologist in Grand Junction, Colorado. Dr. Virgilio is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and Multiple Myeloma.

Experienced in WT1-Related Wilms Tumor Syndromes
Dr. Alicia S. Swink
Hematology Oncology | Hematology | Oncology
Experienced in WT1-Related Wilms Tumor Syndromes
Dr. Alicia S. Swink
Hematology Oncology | Hematology | Oncology

Intermountain Medical Group Grand Junction, LLC

2635 N 7th St, 
Grand Junction, CO 
 (0.5 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Alicia Swink is a Hematologist Oncology specialist and a Hematologist in Grand Junction, Colorado. Dr. Swink is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Familial Colorectal Cancer. Dr. Swink is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. King's expertise for a condition
ConditionClose
    View All 19 Advanced Conditions
    View All 122 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile